Tangram Therapeutics filed a clinical trial application with the U.K. Medicines and Healthcare products Regulatory Agency to launch a Phase I/II study of TGM‑312 in metabolic dysfunction‑associated steatohepatitis (MASH). The submission marks Tangram’s transition of TGM‑312 from preclinical development to first‑in‑human testing in a condition with growing unmet need. MASH (also called metabolic dysfunction‑associated steatohepatitis) refers to fatty‑liver disease associated with metabolic dysfunction and is a leading target for new anti‑fibrotic and metabolic therapies; the MHRA review will determine trial start timing and protocol conditions.